4E2 Stock Chart & Stats
€4.40
€0.20(4.76%)
At close: 4:00 PM EDT
€4.40
€0.20(4.76%)
Day’s Range― - ―
52-Week Range€0.47 - €6.50
Previous CloseN/A
Volume0.00
Average Volume (3M)33.00
Market Cap
€482.78M
Enterprise Value€368.75
Total Cash (Recent Filing)€233.96M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 06, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding104,890,220
10 Day Avg. Volume0
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-4.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.60Price Target Upside186.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.72
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Robust Phase 2 EfficacyDurable, high complete response rates in Phase 2 provide a strong clinical foundation for registrational studies and future uptake in NMIBC. Sustained 12-month CRs and no progressions reduce clinical uncertainty, supporting regulatory case, payer conversations, and a differentiated commercial value proposition.
Regulatory Clarity & Phase 3 PlanAgreement with FDA on a two‑pathway registrational strategy materially cuts program risk versus ambiguous designs. A clear single‑arm and randomized route expands addressable indications, improves planning for enrollment logistics, and increases the probability of an approvable label if trials meet endpoints.
Material Financing & RunwayA sizable cash infusion that funds Phase 3 and additional pipeline work meaningfully reduces near‑term financing risk. Multi‑year runway allows management to focus on execution, enrollment and data readouts without immediate dilution pressure, improving odds of completing registrational programs.
Bears Say
No Revenue / Cash BurnBeing pre‑revenue with ongoing negative operating and free cash flow leaves the company dependent on capital markets and financings. Delays or enrollment setbacks could force further raises, diluting shareholders and constraining long‑term investment capacity absent successful trial outcomes.
Rising G&A And Wider LossesEscalating G&A, driven by higher compensation, and a larger absolute quarterly loss increase fixed cost pressure as development scales. Higher overhead reduces the net runway benefit from financing and raises the breakeven bar post‑approval, making capital efficiency and cost control more critical.
IP Prosecution & Trial Heterogeneity RiskPatent protection depends on successful prosecution; uncertainty delays lengthening exclusivity and could weaken commercial defensibility. Separately, heterogeneous prior‑therapy allowances in Phase 3 create population variability that can dilute observed efficacy, increasing the execution and regulatory risk.
Relmada Therapeutics News
4E2 FAQ
What was Relmada Therapeutics Inc’s price range in the past 12 months?
Relmada Therapeutics Inc lowest stock price was €0.47 and its highest was €6.50 in the past 12 months.
What is Relmada Therapeutics Inc’s market cap?
Relmada Therapeutics Inc’s market cap is €482.78M.
When is Relmada Therapeutics Inc’s upcoming earnings report date?
Relmada Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Relmada Therapeutics Inc’s earnings last quarter?
Relmada Therapeutics Inc released its earnings results on May 12, 2026. The company reported -€0.191 earnings per share for the quarter, missing the consensus estimate of -€0.173 by -€0.017.
Is Relmada Therapeutics Inc overvalued?
According to Wall Street analysts Relmada Therapeutics Inc’s price is currently Undervalued.
Does Relmada Therapeutics Inc pay dividends?
Relmada Therapeutics Inc does not currently pay dividends.
What is Relmada Therapeutics Inc’s EPS estimate?
Relmada Therapeutics Inc’s EPS estimate is -0.17.
How many shares outstanding does Relmada Therapeutics Inc have?
Relmada Therapeutics Inc has 104,890,220 shares outstanding.
What happened to Relmada Therapeutics Inc’s price movement after its last earnings report?
Relmada Therapeutics Inc reported an EPS of -€0.191 in its last earnings report, missing expectations of -€0.173. Following the earnings report the stock price went up 7.5%.
Which hedge fund is a major shareholder of Relmada Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:4E2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relmada Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€12.60 (186.42% Upside)
€12.60 (186.42% Upside)
Blogger Sentiment
Bullish
DE:4E2 Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
704.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
750.32%
Trailing 12-Months
Company Description
Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
4E2 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive momentum: robust phase 2 12-month efficacy and safety data for NDV-01, FDA alignment for a two-pathway Phase 3 registrational program, strengthened IP positioning via a provisional patent filing, and a materially improved balance sheet with ~$234M cash (runway into 2029). Operational advantages (office-based, short administration) and a planned Cipranolone proof-of-concept add to the upside. Key challenges include a significant rise in G&A expense, a modestly larger absolute net loss, patent prosecution uncertainty, and potential variability in Phase 3 patient populations which could affect measured efficacy. Overall, the highlights substantially outweigh the lowlights, but successful execution of the planned mid-2026 trial starts and subsequent enrollment/readouts remain critical.View all DE:4E2 earnings summaries4E2 Stock 12 Month Forecast
Average Price Target
€12.60
▲(186.42% Upside)